Experimental immune cell therapy tested for Tough-to-Treat liver cancers
NCT ID NCT06515314
Summary
This is an early-stage safety study testing a new type of immune cell therapy called HRYZ-T102. It is for adults with advanced liver cancer or other solid tumors that have stopped responding to standard treatments and who have a specific genetic marker (HLA-A 02:03). Researchers will give patients a single infusion of specially modified T-cells designed to target cancer cells and monitor them closely for safety and any signs of tumor response over two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital Affiliated to Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.